Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research

Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects... Letters 2. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell second dose of tocilizumab was administered on day 14, fol- therapy: assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15 lowed by resolution of the fingertip cyanosis and swelling as (1):47-62. doi:10.1038/nrclinonc.2017.148 well as healing of the cutaneous lesions. 3. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-128. doi:10. 1016/j.currproblcancer.2016.12.001 Discussion | Cutaneous toxic effects are very common in im- mune checkpoint inhibitor treatment, showing a broad range 4. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: 3,4 review of dermatologic toxicity associated with programmed cell death of clinical manifestations. However, cutaneous toxic reac- protein-1/programmed death ligand-1 inhibitors and recommendations for tions after CAR-T treatment have rarely been reported. Rubin diagnosis and management. Oncologist. 2018;23(10):1119-1126. doi:10.1634/ et al described 5 patients with skin lesions that might be at- theoncologist.2018-0128 tributed to CAR-T therapy, including secondary cutaneous ma- 5. Rubin CB, Elenitsas R, Taylor L, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. lignant neoplasms, disseminated Staphylococcus infections, 2 2016;75(5):1054-1057. doi:10.1016/j.jaad.2016.06.062 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research

JAMA Dermatology , Volume 156 (9) – Sep 10, 2020

Loading next page...
 
/lp/american-medical-association/clarification-regarding-noninferiority-and-a-discussion-of-model-BDlGLrz8EP
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2020.1310
Publisher site
See Article on Publisher Site

Abstract

Letters 2. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell second dose of tocilizumab was administered on day 14, fol- therapy: assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15 lowed by resolution of the fingertip cyanosis and swelling as (1):47-62. doi:10.1038/nrclinonc.2017.148 well as healing of the cutaneous lesions. 3. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-128. doi:10. 1016/j.currproblcancer.2016.12.001 Discussion | Cutaneous toxic effects are very common in im- mune checkpoint inhibitor treatment, showing a broad range 4. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: 3,4 review of dermatologic toxicity associated with programmed cell death of clinical manifestations. However, cutaneous toxic reac- protein-1/programmed death ligand-1 inhibitors and recommendations for tions after CAR-T treatment have rarely been reported. Rubin diagnosis and management. Oncologist. 2018;23(10):1119-1126. doi:10.1634/ et al described 5 patients with skin lesions that might be at- theoncologist.2018-0128 tributed to CAR-T therapy, including secondary cutaneous ma- 5. Rubin CB, Elenitsas R, Taylor L, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. lignant neoplasms, disseminated Staphylococcus infections, 2 2016;75(5):1054-1057. doi:10.1016/j.jaad.2016.06.062

Journal

JAMA DermatologyAmerican Medical Association

Published: Sep 10, 2020

References